Business
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update
About this update from Verrica Pharmaceuticals Inc.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/35B6rwmMy25cs4KMlGMlxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update.","length":505,"tagName":"p"},{"type":"text","content":"Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.","length":254,"tagName":"p"},{"type":"text","content":"A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.","length":255,"tagName":"p"},{"type":"text","content":"About Verrica Pharmaceuticals Inc.Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verri...